Form 8-K - Current report:
SEC Accession No. 0001819790-25-000077
Filing Date
2025-05-01
Accepted
2025-05-01 16:07:27
Documents
15
Period of Report
2025-05-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tars-20250501.htm   iXBRL 8-K 27922
2 EX-99.1 exhibit991tarsus512025pres.htm EX-99.1 109210
6 picture1a.jpg GRAPHIC 5866
  Complete submission text file 0001819790-25-000077.txt   284474

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20250501.xsd EX-101.SCH 1773
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20250501_lab.xml EX-101.LAB 22530
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20250501_pre.xml EX-101.PRE 13037
17 EXTRACTED XBRL INSTANCE DOCUMENT tars-20250501_htm.xml XML 2736
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

EIN.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 25903042
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)